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Hepatic encephalopathyThe occurrence of epileptic seizures in the presence of hepatic disease is not uncommon in clinical practice.
Selecting an appropriate AED for patients affected by liver failure who have new-onset epileptic seizures can
be challenging. We describe a 64-year-oldman affected by liver cirrhosis. The patient developed partial epilepsy
with secondary generalization because of an intracerebral hemorrhage in the left parieto-occipital regions. After
the neurosurgery procedure, seizures reappeared and were initially managed with levetiracetam. After one
month, the patient experienced clusters of seizures while on stable treatment with levetiracetam. Pregabalin
as add-onwas not tolerated; therefore, he received a low dose of phenobarbital as add-on treatment. The patient
developed hepatic encephalopathy. Phenobarbital was immediately stopped, and oral lacosamide was
added. A rapid recovery of encephalopathy with a 6-month seizure freedom was obtained. The patient
died 6 months later because of progressive impairment of liver function. Lacosamide may represent an al-
ternative to other AEDs in patients with liver failure; however, further prospective evaluation of its efﬁcacy
and safety in this clinical setting is needed.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Selecting an appropriate antiepileptic drug (AED) for patients affect-
ed by liver dysfunction and new-onset epileptic seizures can be
challenging since ﬁrst-line AEDsmay contribute toworsen encephalop-
athy and result in hepatotoxicity. Efﬁcacy, tolerability, and toxicity rep-
resent the main factors inﬂuencing the choice of an AED, mainly when
speciﬁc comorbidity may affect epilepsy [1]. Since the liver and kidney
represent the main organs involved in the elimination of most drugs,
their dysfunction may highly inﬂuence the pharmacokinetics of AEDs
[2]. In the past two decades, the introduction of newer AEDs with a bet-
ter pharmacokinetic proﬁle than traditional AEDs has improved the
management of these patients [2].
Lacosamide (LCM), (R)-2-acetamido-N-benzyl-3-methoxypro-
prionamide, is a new AEDwith selective enhancement of sodium chan-
nel inactivation. Lacosamide is well absorbed after oral administration
(100%) [2], food does not affect the rate or the extent of the absorption,
and the binding to plasma protein is minimal (less than 15%) [3].
Lacosamide is primarily eliminated from the systemic circulation byTor Vergata”, Department of
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95% of LCM is recovered in the urine and b0.5% in the feces. The major
compounds found in the urine include unchanged drug (40%), about
30% as the inactive O-desmethyl metabolite, and a structurally un-
known polar fraction (about 20%). The metabolites do not show phar-
macologic activity. Metabolism is through the CYP450 2C19 without
any signiﬁcant drug interaction. In the presence of mild to moderate
(Child A and B) liver disease, no dose adjustment is usually recom-
mended [2]. Elimination and toxicity in the presence of severe hepatic
failure (Child C) have not been studied [2]. Therefore, LCM may repre-
sent a valid alternative AEDwhen previous treatment failed, and the re-
maining AEDs should be cautiously utilized in patients with hepatic
impairment [2].
2. Report of the case
A 64-year-old man affected by moderate alcoholic liver cirrhosis
(MELD score: 14; Child–Pugh Class B) experienced focal seizures with
secondary generalization characterized by ascending paraesthesias
followed by hypoesthesia and jerks of the right limbs. No prior history
of alcohol-related seizures was obtained. Brain MRI showed an intrace-
rebral hemorrhage in the left parietal–occipital regions. Sodium and
ammonia levels were within normal range. After the neurosurgery pro-
cedure, seizures recurred and were initially managed with levetirace-
tam (LEV) (up to 3000 mg/day). Because of seizure reappearance,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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quickly withdrawn for lack of tolerability (excessive daytime somno-
lence). After onemonth, the patient experienced focal seizureswith sec-
ondary generalization while on stable treatment with levetiracetam
(3000 mg/day); therefore, he was evaluated in the emergency ward
and received phenobarbital (50 mg/day) as add-on treatment. After
24 h, the patient became stuporous, and mental status ﬂuctuated. Met-
abolic encephalopathy was conﬁrmed by EEG showing generalized
polymorphic slowing, diffuse triphasic sharp waves, and left tempo-
ral–parietal PLEDs (Fig. 1A). Blood ammonia levelwas 168 μmol/L (nor-
mal range: 30–85), phenobarbital level was 9 μg/mL (normal range:
15–40), and aspartate aminotransferase and alanine aminotransferase
were slightly altered but substantially unchanged when compared
with previous values. Fluid therapy was instituted. Phenobarbital was
immediately stopped, and a single oral loading dose of LCM (200 mg),
followed approximately 12 h later by 100 mg twice daily up to
200 mg twice a day maintenance dose, was started. By the third day of
LCM therapy, the patient becamemore responsive, and blood ammonia
level was in the reference range. One week later, EEG showed sporadic
interictal sharp waves in temporal–parietal–occipital regions and nor-
mal background activity (Fig. 1B). After six months, the patient was
still seizure-free at follow-up. After this follow-up, the hepatic failure
progressively worsened (MELD score: 20; Child–Pugh Class C); there-
fore, we slowly reduced lacosamide to 200 mg daily in order to avoid
possible hepatic toxicity due to the probable increase of the area under
the curve [2]. Transjugular intrahepatic portosystemic shunt (TIPS) was
performed to treat portal hypertension and previous esophageal bleed-
ing. The patient remained seizure-free, but he was also added to the
liver transplant waiting list. Nevertheless, he died six months later.Fig. 1. Phenobarbital addition induced a widespread abnormal EEG slowing associated with diff
nobarbital withdrawal and lacosamide addition induced a prompt recovery of vigilance level, a
normal background activity. Each vertical column is 1 s of recording time.3. Discussion
The use of AEDs in the presence of hepatic failure is complex and
requires great familiarity with the pharmacokinetics of these agents
[4]. This report showed the common difﬁculties encountered when
hepatically metabolized standard antiseizure medications such as
phenobarbital are prescribed for patients affected by alcoholic liver
cirrhosis. The pharmacokinetics of elimination of many classical
AEDs becomes unpredictable, and the threshold for developing or de-
tecting central nervous system side effects diminishes. These problems
may contribute to worsening encephalopathy. LEV is considered as a
valid treatment for patients affected by liver dysfunction and epilepsy,
though a dose reduction may be needed in patients with severe liver
cirrhosis [5]. We found only a previous case report describing an acute
liver failure in a young patient affected by an unspeciﬁed epileptic dis-
order. This subject was previously treated with LEV and LCM, and the
liver dysfunction appeared after the increase of LEV dose during a con-
vulsive status epilepticus (CSE) [6]. Although liver biopsy conﬁrmed a
toxic origin of hepatic failure, speciﬁc clinical details are lacking (other
treatments, CSE outcome, EEG and MRI ﬁndings, LEV and/or LCMwith-
drawal); therefore even if possible, this report does not allow the con-
clusion to be made that LEV treatment induced the acute liver failure
[6].
PGBwas also considered in our patient because it is not metabolized
by the liver and is excreted renally. It has negligible binding to plas-
ma proteins and does not have any signiﬁcant drug–drug interac-
tions [7]. The pharmacokinetic properties of PGB are favorable, but
it provoked a signiﬁcant sleepiness in our patient when added
to LEV, leading to PGB discontinuation. A low dose of phenobarbitaluse triphasic sharp waves and left temporal–parietal paroxysms (A). One week later, phe-
nd EEG (B) showed rare interictal sharp waves in temporal–parietal–occipital regions and
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by mental status ﬂuctuations associated with EEG slowing and
triphasic sharp waves. Phenobarbital withdrawal and LCM addition
induced a prompt recovery of hepatic encephalopathy and seizure
freedom. Lacosamide was chosen as an alternative to other AEDs be-
cause of its favorable pharmacokinetic properties. Lacosamide may
offer some advantages in the treatment of epilepsy in patients with
liver failure. Lacosamide is rapidly and completely absorbed after
oral administration. Its bioavailability is not affected by food, and its
pharmacokinetics are linear and time-invariant. It has a 13-hour half-
life, and a steady state is achieved after 2 days of twice-daily dosing.
In addition, LCMhas properties thatmake it unlikely to produce clinical-
ly signiﬁcant drug–drug interactions in patients with liver cirrhosis. The
major metabolic pathway is enzymatic hydrolysis, producing an inac-
tive O-desmethyl metabolite, but more than 40% of the dose is excreted
unchanged in the urine [2,3]. In addition, the 12 months of seizure
freedom obtained after LCM addition represented a signiﬁcant im-
provement of quality of life in a patient affected by alcoholic cirrhosis
with a poor prognosis.
Although a single case report does not allow any generalization, we
can state that LCMmay represent a valid alternative when LEV and PGB
are ineffective or not tolerated in patients withmoderate to severe liverdysfunction. However, further prospective evaluation of its effective-
ness and safety in this clinical setting is needed.
Conﬂict of interests
No conﬂict of interest.
References
[1] Anderson GD, Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with he-
patic or renal impairment. Clin Pharmacokinet 2014 Jan;53(1):29–49.
[2] Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol
2014;119:417–32.
[3] Harris JA, Murphy JA. Lacosamide and epilepsy. CNS Neurosci Ther 2011 Dec;17(6):
678–82.
[4] Lacerda G, Krummel T, Sabourdy C, Ryvlin P, Hirsch E. Optimizing therapy of seizures in
patients with renal or hepatic dysfunction. Neurology 2006 Dec 26;67(12 Suppl. 4):
S28–33.
[5] Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006 Apr;15(3):
156–64.
[6] Gutiérrez-Grobe Y, Bahena-Gonzalez JA, Herrera-Gomar M, Mendoza-Diaz P, García-
López S, González-Chon O. Acute liver failure associated with levetiracetam and
lacosamide combination treatment for unspeciﬁed epileptic disorder. Case Rep
Emerg Med 2013;2013:634174. http://dx.doi.org/10.1155/2013/634174.
[7] Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice.
Epilepsia 2004;45(Suppl. 6):13–8.
